Septerna is the 23rd biotech to go public this year, raising funds to advance its lead candidate, a treatment for ...

Septerna CEO Jeffrey Finer rang the opening bell on the Nasd | South San Francisco-based Septerna has scored with an upsized ...

Septerna's shares rose about 31% in their market debut on Friday, giving the Goldman Sachs-backed biotech firm a valuation of ...

Septerna may be yet to disclose “any meaningful clinical data,” but the biotech clearly thinks there will be investor ...

We recently published a list of 10 Biggest Stocks with Negative Beta to Consider. In this article, we are going to take a ...

Goldman Sachs-backed Septerna would be valued around $750 million. Drug developers have achieved resounding success in the ...

Nascent clinical biotech Septerna added to the slight uptick in IPO fervor this fall with its $288 million Nasdaq listing on ...

Researchers at the Paul Scherrer Institute PSI have succeeded in elucidating the structure of specific photoreceptors.

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.